论文部分内容阅读
目的 :探讨癌症化疗患者应用重组人粒细胞集落刺激因子(rh G-CSF)持续时长的相关因素。方法 :回顾性分析在本院接受化疗的癌症患者且应用rh G-CSF治疗的患者118例,根据应用重组人粒细胞集落刺激因子持续平均时长,将患者分为长持续时间组和短持续时间组,比较两组患者的性别比例、年龄分布、BMI指数,肿瘤类型,肿瘤分级,中性粒细胞含量,血红蛋白,血小板计数,血肌酐,卡氏评分,化疗方案确定癌症化疗患者应用重组人粒细胞集落刺激因子持续时长的相关影响因素,再通过多因素分析确定癌症化疗患者应用重组人粒细胞集落刺激因子持续时长的独立影响因素。结果 :通过单因素分析确定年龄分布、BMI指数,肿瘤分级,中性粒细胞含量为癌症化疗患者应用重组人粒细胞集落刺激因子持续时长的相关影响因素;通过多因素分析确定年龄分布、BMI指数,肿瘤分级,中性粒细胞含量为癌症化疗患者应用重组人粒细胞集落刺激因子持续时长的独立影响因素。结论 :对于癌症化疗患者应用rh G-CSF药物需要足够的持续时长才能起作用,对于年龄较大,BMI指数较低,肿瘤分级较晚以及中性粒细胞含量较低的患者需要应用rh G-CSF药物更长的时间,要引起临床足够的重视。
Objective: To investigate the related factors of the duration of rhG-CSF in cancer patients undergoing chemotherapy. Methods: A retrospective analysis of 118 patients with cancer treated with rhG-CSF and chemotherapy in our hospital was retrospectively analyzed. Patients were divided into long-duration group and short-duration group according to the average sustained duration of application of recombinant human granulocyte-colony stimulating factor The gender, age distribution, BMI index, tumor type, tumor grade, neutrophil content, hemoglobin, platelet count, serum creatinine, Karnofsky score and chemotherapy regimen were compared between the two groups. Cell colony-stimulating factor duration of influence factors, and then through multivariate analysis to determine the cancer chemotherapy patients with recombinant human granulocyte colony-stimulating factor duration of independent factors. Results: The age distribution, BMI index, tumor grade and neutrophil content were determined by univariate analysis. The influencing factors of the duration of recombinant human granulocyte colony-stimulating factor in patients with cancer chemotherapy were determined. The age distribution, BMI index , Tumor grade and neutrophil content were independent influencing factors for the duration of recombinant human granulocyte colony-stimulating factor in patients with cancer chemotherapy. Conclusions: The use of rhG-CSF drugs in cancer chemotherapy patients requires a sufficient duration of action to be effective. Patients with older age, lower BMI index, late tumor grade, and lower neutrophil granulocyte volume require rhG- CSF drugs for a longer period of time, to cause enough attention in clinical.